NCT06830356Recruiting
Somatostatin Receptor PET Imaging to Guide Radiotherapy Dose Escalation in High Risk Meningiomas.
Source: ClinicalTrials.gov · Last updated 17 Feb 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
High-risk meningiomas always require postsurgical radiation treatment. Recent evidence has shown that increased radiation therapy dose may be associated with increased intracranial control of disease. In order to better define the volume of radiation treatment, the addition of PET imaging with somatostatin receptor tracers adds additional information compared to encephalon MRI with MoC alone.The present study aims to investigate whether radiation treatment with higher doses than the standard and defined using PET imaging can be safe and at the same time effective in order to increase progression-free survival in high-risk meningiomas.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 53 (estimated)
- First submitted
- 11 Feb 2025
- Start date
- 23 Dec 2024
- Primary completion date
- 23 Dec 2037
- Lead sponsor
- Centro di Riferimento Oncologico - Aviano
- NCT number
- NCT06830356
What you commit to
- Study type: Interventional
- Planned participants: 53
- From 23 Dec 2024 to the primary completion date, 23 Dec 2037
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Refusal to radiation treatment (i.e., absence of signed informed consent);
- Other concomitant oncologic therapies
- Grade I meningiomas or Grade II meningiomas if operated on at first diagnosis with radical resection;
Other
- Current pregnancy;
- Inability to perform MRI with MoC or PET.
Who the study is looking for
- Age ≥ 16 years;
- Ability to express appropriate informed consent to treatment;
- Diagnosis of grade III meningioma (regardless of presence of residual) or diagnosis of recurrence of grade II meningioma (regardless of presence of residual) or first diagnosis of grade II meningioma with presence of residual;
- In case of recurrence, confirmation can be either histological or radiological;
- Not previous brain-level radiotherapy;
- Performance status: ECOG=0-2.
Age in the registry: 16 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Centro di Riferimento Oncologico di Aviano (CRO) Coordinator of this site? Confirm its status | Aviano | Italy | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.